Eloxx Pharmaceuticals ELOX

NASDAQ ELOX

$13.20 +0.00 (+0.00%)

As of: Oct 21, 2026 · 3:59 PM EDT

Eloxx Pharmaceuticals (ELOX) stock price is $13.20, unchanged on the day, as of Oct 21, 2026. It has a market cap of $89.68Mn, and is classified in the Pharmaceuticals industry (Healthcare sector).

Key Stats

Market Cap89.68 Mn

P/E-7.56

Div. Yield0.00

Add ratio to table…

About

Eloxx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing small molecule therapeutics that modulate the ribosome to promote readthrough of premature stop codons caused by nonsense mutations. The company's approach targets ribosomal subunits to enable the production of full length functional proteins in patients whose genetic diseases are driven by nonsense mutations. According to the Human Gene Mutation Database, nonsense mutations account for an estimated 10% to 12% of patients across any given genetic disease and there are more than 7,000 inherited disorders affecting roughly 350 million people worldwide. Eloxx Pharmaceuticals, Inc.'s lead product candidate exaluren is being advanced for the treatment of rare kidney diseases such as autosomal recessive Alport Syndrome and nonsense mutation associated autosomal dominant polycystic kidney disease. The company has also exclusively licensed its second product candidate ZKN 013 to Almirall, S A for development in rare skin diseases including recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa. By concentrating on ribosome modulation, Eloxx Pharmaceuticals, Inc. seeks to address a significant unmet need in genetic therapeutics where few disease modifying options exist.

Eloxx Pharmaceuticals, Inc. generates revenue primarily through licensing and collaboration agreements that provide upfront payments, milestone payments, and future royalties. The agreement with Almirall, S A signed in March 2024 grants Almirall exclusive global rights to develop and commercialize ZKN 013 for use in all 20 indications including recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa. Under this arrangement Eloxx Pharmaceuticals, Inc. received an upfront payment of $3 million and a development milestone payment of $3 million in 2024. The company is eligible to receive up to approximately $470 million in additional development, regulatory, and commercial milestone payments plus tiered royalties on global sales of ZKN 013. In addition to partnership revenues, Eloxx Pharmaceuticals, Inc. has financed its operations through the sale of equity, debt securities, and grant funding, though these sources are not classified as operating revenue. As of March 31, 2026, Eloxx Pharmaceuticals, Inc. reported cash and cash equivalents of $6.4 million and an accumulated deficit of $304.3 million.

Eloxx Pharmaceuticals, Inc. operates in the highly specialized niche of ribosome modulating therapies for nonsense mutation mediated genetic diseases. This field addresses an estimated 10% to 12% of patients across more than 7,000 inherited disorders affecting roughly 350 million people worldwide. The company's competitive advantage lies in its proprietary small molecule approach that directly targets ribosomal function to restore full length protein expression, differing from gene therapy, enzyme replacement, or antisense oligonucleotide strategies. While the filing does not name specific competitors, the broader landscape includes other readthrough agents and rare disease therapeutics companies pursuing similar mechanistic avenues. Eloxx Pharmaceuticals, Inc. differentiates itself through clinical data showing improvements in kidney biopsy markers such as reduced podocyte foot process effacement and improved glomerular basement membrane width, supporting the mechanistic rationale of its platform. Preclinical organoid and cellular models have demonstrated increased expression of polycystin 1 and polycystin 2 following treatment with exaluren providing a basis for development in nonsense mutation associated autosomal dominant polycystic kidney disease.

Eloxx Pharmaceuticals, Inc. serves patients with rare genetic diseases caused by nonsense mutations, initially focusing on individuals with autosomal recessive Alport Syndrome and nonsense mutation associated autosomal dominant polycystic kidney disease for its exaluren program. Through its licensing arrangement, the company indirectly serves patients with recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa who are targeted by Almirall, S A's development of ZKN 013. Almirall, S A estimates that approximately 4,000 patients with nonsense mutations exist in these skin diseases across the major markets of the United States, Japan, and Western Europe. Patients with autosomal recessive Alport Syndrome experience progressive kidney fibrosis and hearing loss while those with nonsense mutation associated autosomal dominant polycystic kidney disease suffer from hypertension, kidney stones, urinary tract infections, heart valve abnormalities, hematuria, and increased risk of aortic aneurysm. Patients with recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa suffer severe skin blistering, wounds, internal lesions, and face heightened risk of skin cancer and severe malnutrition.

Investment Thesis

▲ Bull case

Eloxx Pharmaceuticals is strategically positioned to capitalize on a significant unmet medical need in the treatment of genetic disorders caused by nonsense mutations, which affect millions of patients globally and represent a substantial market opportunity for ribosome-modulating therapies. The company's lead candidate, ELX-02, is designed to promote ribosomal readthrough of premature stop codons, enabling the production of functional full-length proteins in diseases such as cystic fibrosis and Duchenne muscular dystrophy, where current therapies are either symptomatic or limited to specific mutation types. This mechanism addresses a root cause rather than symptoms, potentially offering disease-modifying effects that could command premium pricing and long-term patient adherence, especially in populations with limited treatment options. The recent public offering, which raised $66.0 million in gross proceeds, provides Eloxx with a strengthened balance sheet to advance its clinical programs through critical milestones, including potential Phase 2 data readouts, without immediate dilution pressure, thereby de-risking near-term execution and extending its cash runway into 2027. This financial flexibility allows the company to invest in manufacturing scale-up, regulatory strategy, and potential biomarker development, which are essential for accelerating partnerships or acquisitions by larger pharmaceutical firms seeking to expand their rare disease portfolios.
The pricing of the offering at $11.00 per share reflects investor confidence in Eloxx's scientific platform and pipeline potential, particularly given the company's focus on nonsense mutation disorders, which are increasingly recognized as a convergent pathway across multiple high-prevalence genetic diseases. Unlike gene therapy approaches that face challenges with delivery, immunogenicity, and manufacturing complexity, Eloxx's small molecule approach offers advantages in oral administration, tissue penetration, and repeat dosing, which could improve patient quality of life and reduce healthcare system burden. The involvement of reputable institutional investors through the underwriting syndicate, including Leerink Partners and Guggenheim Securities, signals sophisticated market validation of the company's de-risking progress and long-term value creation potential, especially as preclinical and early clinical data continue to support target engagement and safety. Furthermore, the use of pre-funded warrants at $10.99 effectively locks in additional capital commitment from investors who are confident in the company's near-term execution, reducing the likelihood of a dilutive down-round and aligning stakeholder interests with sustained share price appreciation. This structure also minimizes overhang concerns, as the warrants are exercisable at a nominal $0.01, making them likely to be exercised regardless of short-term market fluctuations, thereby providing a term volatility.
Eloxx's ribosome-targeting technology has broader applicability beyond its current indications, with potential to address other nonsense mutation-driven conditions such as inherited metabolic disorders, retinal dystrophies, and certain oncogenic pathways, creating multiple future growth vectors that are not yet fully priced into the stock. The company's intellectual property estate, which includes composition-of-matter patents covering novel chemical scaffolds and methods of use, provides a durable competitive barrier that could protect its market position for over a decade, especially as regulatory pathways for readthrough therapeutics become more defined through FDA guidance and precedent-setting approvals. The recent offering proceeds will enable Eloxx to pursue IND-enabling studies for additional candidates, expanding its pipeline and reducing reliance on any single asset, which is critical for long-term valuation resilience in the volatile biotech sector. Moreover, as regulatory agencies increasingly recognize the therapeutic value of translational readthrough approaches—evidenced by recent orphan drug designations and accelerated pathways for similar modalities—Eloxx stands to benefit from favorable review timelines, potential priority review vouchers, and eligibility for rare disease tax credits, all of which could significantly enhance the economics of future commercialization.

Eloxx Pharmaceuticals is strategically positioned to capitalize on a significant unmet medical need in the treatment of genetic disorders caused by nonsense mutations, which affect millions of patients globally and represent a substantial market opportunity for ribosome-modulating therapies. The company's lead candidate, ELX-02, is designed to promote ribosomal readthrough of premature stop codons, enabling the production of functional full-length proteins in diseases such as cystic fibrosis and Duchenne muscular dystrophy, where current therapies are either symptomatic or limited to specific mutation types. This mechanism addresses a root cause rather than symptoms, potentially offering disease-modifying effects that could command premium pricing and long-term patient adherence, especially in populations with limited treatment options. The recent public offering, which raised $66.0 million in gross proceeds, provides Eloxx with a strengthened balance sheet to advance its clinical programs through critical milestones, including potential Phase 2 data readouts, without immediate dilution pressure, thereby de-risking near-term execution and extending its cash runway into 2027. This financial flexibility allows the company to invest in manufacturing scale-up, regulatory strategy, and potential biomarker development, which are essential for accelerating partnerships or acquisitions by larger pharmaceutical firms seeking to expand their rare disease portfolios.
The pricing of the offering at $11.00 per share reflects investor confidence in Eloxx's scientific platform and pipeline potential, particularly given the company's focus on nonsense mutation disorders, which are increasingly recognized as a convergent pathway across multiple high-prevalence genetic diseases. Unlike gene therapy approaches that face challenges with delivery, immunogenicity, and manufacturing complexity, Eloxx's small molecule approach offers advantages in oral administration, tissue penetration, and repeat dosing, which could improve patient quality of life and reduce healthcare system burden. The involvement of reputable institutional investors through the underwriting syndicate, including Leerink Partners and Guggenheim Securities, signals sophisticated market validation of the company's de-risking progress and long-term value creation potential, especially as preclinical and early clinical data continue to support target engagement and safety. Furthermore, the use of pre-funded warrants at $10.99 effectively locks in additional capital commitment from investors who are confident in the company's near-term execution, reducing the likelihood of a dilutive down-round and aligning stakeholder interests with sustained share price appreciation. This structure also minimizes overhang concerns, as the warrants are exercisable at a nominal $0.01, making them likely to be exercised regardless of short-term market fluctuations, thereby providing a term volatility.
Eloxx's ribosome-targeting technology has broader applicability beyond its current indications, with potential to address other nonsense mutation-driven conditions such as inherited metabolic disorders, retinal dystrophies, and certain oncogenic pathways, creating multiple future growth vectors that are not yet fully priced into the stock. The company's intellectual property estate, which includes composition-of-matter patents covering novel chemical scaffolds and methods of use, provides a durable competitive barrier that could protect its market position for over a decade, especially as regulatory pathways for readthrough therapeutics become more defined through FDA guidance and precedent-setting approvals. The recent offering proceeds will enable Eloxx to pursue IND-enabling studies for additional candidates, expanding its pipeline and reducing reliance on any single asset, which is critical for long-term valuation resilience in the volatile biotech sector. Moreover, as regulatory agencies increasingly recognize the therapeutic value of translational readthrough approaches—evidenced by recent orphan drug designations and accelerated pathways for similar modalities—Eloxx stands to benefit from favorable review timelines, potential priority review vouchers, and eligibility for rare disease tax credits, all of which could significantly enhance the economics of future commercialization.

▼ Bear case

Eloxx Pharmaceuticals remains a clinical-stage company with no approved products and a history of failing to translate preclinical promise into consistent clinical efficacy, raising significant concerns about the translatability of its ribosomal readthrough platform in human patients. Despite years of development, the company has not yet demonstrated statistically significant and clinically meaningful improvement in primary endpoints in any of its trials, and its reliance on surrogate biomarkers or exploratory outcomes increases the risk that positive early signals may not hold up in pivotal studies, particularly given the heterogeneity of nonsense mutation phenotypes and variable residual protein function across tissues. The recent $66.0 million offering, while providing short-term liquidity, underscores the company's ongoing dependence on dilutive financing to sustain operations, as it has yet to generate any revenue or establish a path to profitability, with cumulative losses continuing to mount and cash burn remaining high relative to its milestone progress. This persistent need for capital raises increases the likelihood of further dilution, especially if clinical timelines slip or data fails to meet expectations, which could erode shareholder value and deter long-term institutional investment.
The ribosomal readthrough approach faces inherent biological limitations that may cap its therapeutic potential, including the risk of generating truncated or dysfunctional proteins due to inefficient or erroneous readthrough, potential disruption of normal translation fidelity leading to proteotoxic stress, and variable efficacy across different mutation types and genetic backgrounds, which could limit the addressable patient population despite the broad theoretical applicability of the platform. Furthermore, the company's focus on ultra-rare or niche subtypes of larger diseases (e.g., specific nonsense mutation cohorts in cystic fibrosis) may result in overly fragmented markets that are difficult to serve commercially, even if approval is achieved, due to high costs of drug development, limited pricing power in constrained payer environments, and challenges in identifying and diagnosing eligible patients at scale. These commercialization hurdles are compounded by the absence of any established pricing precedent for readthrough therapeutics, making revenue forecasting highly speculative and increasing the risk that peak sales estimates will fall significantly short of analyst expectations, thereby undermining the valuation implied by the recent offering price.
Eloxx operates in an increasingly competitive landscape where alternative strategies for treating nonsense mutations—such as next-generation gene editing (e.g., base and prime editing), antisense oligonucleotides, and suppressor tRNA therapies—are advancing rapidly and may offer more durable, one-time, or higher-efficacy solutions that could render small molecule readthrough approaches obsolete before Eloxx achieves commercial scale. The company's lack of partnerships or licensing deals with major pharmaceutical firms, despite years of preclinical development, raises questions about external validation of its technology's superiority or differentiation, suggesting that larger players may view its approach as incremental or too risky compared to emerging modalities with clearer mechanistic advantages. Additionally, the recent offering was priced at a level that implies significant future success is already discounted into the stock, leaving little room for error; any clinical delay, unfavorable regulatory feedback, or failure to secure a partnership could trigger a sharp reevaluation of the company's prospects, particularly given its high cash burn rate and absence of near-term inflection points beyond ongoing early-stage trials. Without a clear, near-term catalyst that demonstrates definitive clinical advantage over placebo or standard of care, the stock remains vulnerable to sentiment-driven volatility and downside pressure from profit-taking or sector rotation away from speculative biotech names.

Eloxx Pharmaceuticals remains a clinical-stage company with no approved products and a history of failing to translate preclinical promise into consistent clinical efficacy, raising significant concerns about the translatability of its ribosomal readthrough platform in human patients. Despite years of development, the company has not yet demonstrated statistically significant and clinically meaningful improvement in primary endpoints in any of its trials, and its reliance on surrogate biomarkers or exploratory outcomes increases the risk that positive early signals may not hold up in pivotal studies, particularly given the heterogeneity of nonsense mutation phenotypes and variable residual protein function across tissues. The recent $66.0 million offering, while providing short-term liquidity, underscores the company's ongoing dependence on dilutive financing to sustain operations, as it has yet to generate any revenue or establish a path to profitability, with cumulative losses continuing to mount and cash burn remaining high relative to its milestone progress. This persistent need for capital raises increases the likelihood of further dilution, especially if clinical timelines slip or data fails to meet expectations, which could erode shareholder value and deter long-term institutional investment.
The ribosomal readthrough approach faces inherent biological limitations that may cap its therapeutic potential, including the risk of generating truncated or dysfunctional proteins due to inefficient or erroneous readthrough, potential disruption of normal translation fidelity leading to proteotoxic stress, and variable efficacy across different mutation types and genetic backgrounds, which could limit the addressable patient population despite the broad theoretical applicability of the platform. Furthermore, the company's focus on ultra-rare or niche subtypes of larger diseases (e.g., specific nonsense mutation cohorts in cystic fibrosis) may result in overly fragmented markets that are difficult to serve commercially, even if approval is achieved, due to high costs of drug development, limited pricing power in constrained payer environments, and challenges in identifying and diagnosing eligible patients at scale. These commercialization hurdles are compounded by the absence of any established pricing precedent for readthrough therapeutics, making revenue forecasting highly speculative and increasing the risk that peak sales estimates will fall significantly short of analyst expectations, thereby undermining the valuation implied by the recent offering price.
Eloxx operates in an increasingly competitive landscape where alternative strategies for treating nonsense mutations—such as next-generation gene editing (e.g., base and prime editing), antisense oligonucleotides, and suppressor tRNA therapies—are advancing rapidly and may offer more durable, one-time, or higher-efficacy solutions that could render small molecule readthrough approaches obsolete before Eloxx achieves commercial scale. The company's lack of partnerships or licensing deals with major pharmaceutical firms, despite years of preclinical development, raises questions about external validation of its technology's superiority or differentiation, suggesting that larger players may view its approach as incremental or too risky compared to emerging modalities with clearer mechanistic advantages. Additionally, the recent offering was priced at a level that implies significant future success is already discounted into the stock, leaving little room for error; any clinical delay, unfavorable regulatory feedback, or failure to secure a partnership could trigger a sharp reevaluation of the company's prospects, particularly given its high cash burn rate and absence of near-term inflection points beyond ongoing early-stage trials. Without a clear, near-term catalyst that demonstrates definitive clinical advantage over placebo or standard of care, the stock remains vulnerable to sentiment-driven volatility and downside pressure from profit-taking or sector rotation away from speculative biotech names.

Consolidation Items Breakdown of Revenue (2024)

History

Peer percentiles

How Eloxx Pharmaceuticals ranks

Ranked against the 668 companies in Pharmaceuticals and Biotechnology58 metrics · as of Oct 21, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −7.56xMedian 16.8x 62^nd
P/FCFNegative free cash flow −8.30xMedian 18.3x 58^th
P/Operating cash flowNegative operating cash flow −8.30xMedian 17.0x 58^th
P/S —Median 9.38x No data —
P/B 1.93xMedian 2.17x 56^th
P/Tangible book 1.93xMedian 2.42x 59^th
EV/EBITDA —Median 15.7x No data —
EV/EBITNegative EBIT −2.50xMedian 19.8x 38^th
EV/Revenue —Median 6.59x No data —
EV/FCFNegative free cash flow −2.56xMedian 19.2x 30^th
EV/Operating cash flowNegative operating cash flow −2.56xMedian 16.0x 29^th
PEG (3Y EPS CAGR)Negative earnings −0.10Median 0.33 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) —Median 10.2% No data —
Revenue CAGR (3Y) —Median 10.2% No data —
Gross profit growth (1Y) —Median 10.6% No data —
Gross profit CAGR (3Y) —Median 10.7% No data —
Operating income growth (1Y) −5.5%Median 0.0% 45^th
Operating income CAGR (3Y) 21.4%Median 1.6% 74^th
Net income growth (1Y) −17.6%Median −5.1% 44^th
Net income CAGR (3Y) 21.4%Median −0.4% 74^th
EPS growth (1Y) 94.0%Median 21.0% 90^th
EPS CAGR (3Y) 75.7%Median 25.3% 90^th
Operating cash flow growth (1Y) −79.6%Median 0.3% 12^th
Operating cash flow CAGR (3Y) 20.5%Median 2.4% 73^rd
Free cash flow growth (1Y) −79.6%Median 0.3% 12^th
Free cash flow CAGR (3Y) 20.6%Median 3.3% 72^nd

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin —Median 74.0% No data —
EBITDA margin —Median −216% No data —
Operating margin —Median −230% No data —
Pretax margin —Median −223% No data —
Net margin —Median −230% No data —
FCF margin —Median −168% No data —
Operating cash flow margin —Median −157% No data —
Return on equity −56.7%Median −53.5% 48^th
Return on assets −30.6%Median −42.0% 62^nd
Return on invested capital —Median −5.3% No data —
Return on capital employed −58.2%Median −46.0% 41^st
Asset turnover —Median 0.18x No data —
Cash conversion (OCF / net income)Net income is not positive 0.91xMedian 1.21x Not meaningful —
Stock comp / revenue —Median 27.5% No data —

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets —Median 20.0% No data —
Debt / equity —Median 0.26x No data —
Net debt / EBITDA —Median 1.82x No data —
Debt / FCF —Median 3.03x No data —
Liabilities / assets 26.8%Median 32.8% 57^th
Equity / assets 73.2%Median 67.2% 57^th
Interest coverage —Median −10.1x No data —
Current ratio 3.74xMedian 4.48x 45^th
Quick ratio 3.65xMedian 3.72x 50^th
Cash ratio 3.65xMedian 3.34x 52^nd
Altman Z-score —Median −0.62 No data —

Peer group

Peer Comparison

Companies in the Pharmaceuticals

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,136.97 Bn	42.57	14.27	54.91 Bn
2	JNJ	Johnson & Johnson	619.72 Bn	29.46	6.33	49.04 Bn
3	ABBV	AbbVie Inc.	503.40 Bn	79.78	7.82	70.82 Bn
4	MRK	Merck & Co., Inc.	370.15 Bn	116.66	5.56	53.91 Bn
5	NVS	Novartis Ag	298.64 Bn	18.93	5.45	9.59 Bn
6	AZN	Astrazeneca Plc	261.07 Bn	24.99	4.45	32.35 Bn
7	AMGN	Amgen Inc	237.00 Bn	27.11	6.22	57.30 Bn
8	ELOX	Eloxx Pharmaceuticals, Inc.	0.09 Bn	-7.56	-	-